Back to Watchlist

Evidence memo

Retatrutide

Also tracked as: LY3437943, triple agonist

An investigational incretin-pathway drug with strong obesity signals and a late-stage trial program, but no approved use yet.

Phase 2 / Phase 3 Investigational

Evidence status

Watch closely. Evidence level: Phase 2 / Phase 3.

Claim being evaluated

Whether a multi-receptor incretin approach can deliver durable obesity and cardiometabolic outcomes that justify the safety and tolerability tradeoffs.

Why people care

Retatrutide sits near the center of obesity-drug attention because early human data suggested large body-weight effects and because broader outcomes trials are underway.

Signal so far

Peer-reviewed phase 2 evidence supports a strong weight-loss signal. Later-stage studies are the evidence boundary that matters next.

Biggest unknown

Longer-term benefit-risk, discontinuation patterns, lean-mass effects, cardiovascular and renal outcomes, and whether sponsor-reported late-stage results replicate in full peer-reviewed data.

Safety/regulatory boundary

Retatrutide remains investigational. Internet-market products using the name should not be treated as the studied drug product.

Watch next

Full phase 3 publications, regulatory filings, adverse-event patterns, lean-mass data, and outcomes beyond body weight.

Evidence interpretation

A high-signal obesity candidate, but the Watchlist read stays provisional until late-stage outcomes and regulatory review define the actual clinical boundary.

References